BTIG on Climb Bio (CLYM): FDA fast track for Budoprutug in pMN 'validating event'
Tweet Send to a Friend
BTIG analyst Julian Harrison reiterated a Buy rating and $8.00 price target on Climb Bio (NASDAQ: CLYM)The analyst commented, "Budoprutug ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
